Bain Capital Life Sciences Investors, LLC

Person Signing this Report on Behalf of Reporting Manager:

Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on May 28, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 8,525,000 shares of DVAX common stock.The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 30, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 4,571,139 shares of SVRA common stock.The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 9, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 1,250,000 shares of XFOR common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 14, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise or conversion. As of December 31, 2020, such persons held an aggregate of 4,000,000 shares of SYRS common stock.

Other Included Managers (5):